Publications

@article{Valea2018-yp,

title = {Immune response to the hepatitis B antigen in the RTS,S/AS01  malaria vaccine, and co-administration with pneumococcal  conjugate and rotavirus vaccines in African children: A  randomized controlled trial},

author = {Innocent Val\'{e}a and Samuel Adjei and Effua Usuf and Ousmane Traore and Daniel Ansong and Halidou Tinto and Harry Owusu Boateng and Amanda Leach and Athanase Mwinessobaonfou Some and Patrick Buabeng and Johan Vekemans and Louis Arnaud Nana and Amos Kotey and Pascale Vandoolaeghe and Florence Ouedraogo and David Sambian and Marc Lievens and Marc Christian Tahita and Theresa Rettig and Erik Jongert and Palpouguini Lompo and Ali Idriss and Dorota Borys and Sayouba Ouedraogo and Frank Prempeh and Md Ahsan Habib and Lode Schuerman and Hermann Sorgho and Tsiri Agbenyega},

doi = {10.1080/21645515.2018.1442996},

issn = {2164-554X 2164-5515},

year  = {2018},

date = {2018-06-01},

urldate = {2018-06-01},

journal = {Hum. Vaccin. Immunother.},

volume = {14},

number = {6},

pages = {1489--1500},

abstract = {The RTS,S/AS01 malaria vaccine (Mosquirix) reduces the incidence 

 of Plasmodium falciparum malaria and is intended for routine 

 administration to infants in Sub-Saharan Africa. We evaluated the 

 immunogenicity and safety of 10-valent pneumococcal non-typeable 

 Haemophilus influenzae protein D conjugate vaccine (PHiD-CV; 

 Synflorix) and human rotavirus vaccine (HRV; Rotarix) when 

 co-administered with RTS,S/AS01 ( www.clinicaltrials.gov 

 NCT01345240) in African infants. 705 healthy infants aged 8-12 

 weeks were randomized to receive three doses of either RTS,S/AS01 

 or licensed hepatitis B (HBV; Engerix B) vaccine (control) 

 co-administered with diphtheria-tetanus-acellular 

 pertussis-Haemophilus influenzae type-b-conjugate vaccine 

 (DTaP/Hib) and trivalent oral poliovirus vaccine at 8-12-16 weeks 

 of age, because DTaP/Hib was not indicated before 8 weeks of age. 

 The vaccination schedule can still be considered broadly 

 applicable because it was within the age range recommended for 

 EPI vaccination. PHiD-CV or HRV were either administered together 

 with the study vaccines, or after a 2-week interval. Booster 

 doses of PHiD-CV and DTaP/Hib were administered at age 18 months. 

 Non-inferiority of anti-HBV surface antigen antibody 

 seroprotection rates following co-administration with RTS,S/AS01 

 was demonstrated compared to the control group (primary 

 objective). Pre-specified non-inferiority criteria were reached 

 for PHiD-CV (for 9/10 vaccine serotypes), HRV, and aP antigens 

 co-administered with RTS,S/AS01 as compared to HBV 

 co-administration (secondary objectives). RTS,S/AS01 induced a 

 response to circumsporozoite protein in all groups. Pain and low 

 grade fever were reported more frequently in the PHiD-CV group 

 co-administered with RTS,S/AS01 than PHiD-CV co-administered with 

 HBV. No serious adverse events were considered to be 

 vaccine-related. RTS,S/AS01 co-administered with pediatric 

 vaccines had an acceptable safety profile. Immune responses to 

 RTS,S/AS01 and to co-administered PHiD-CV, pertussis antigens and 

 HRV were satisfactory.},

keywords = {RTS, S; co-administration; hepatitis B; immunogenicity; malaria;   plasmodium falciparum; pneumococcal conjugate vaccine; vaccine},

pubstate = {published},

tppubtype = {article}

}